Bayer Disagrees With French Court Decision on Roundup
January 15 2019 - 12:14PM
Dow Jones News
By Donato Paolo Mancini
Bayer AG (BAYN.XE) said late Tuesday that it disagrees with the
decision taken by a French court to cancel the marketing
authorization for Roundup 360, a glyphosate product it inherited
after acquiring Monsanto last year.
Bayer pointed to scientific evidence it said proves glyphosate
isn't carcinogenic, and said it is currently reviewing the decision
and considering its legal options.
Bayer is currently embroiled in a high-stakes legal challenge in
the U.S. over whether glyphosate can cause cancer, after it lost a
high-profile case last summer. The German chemicals giant claimed
an essential victory earlier this month when it successfully asked
for a procedural change in a pivotal trial on the same issue.
Shares in Bayer have lost 37% in the past 12 months, and closed
0.3% higher Tuesday.
Write to Donato Paolo Mancini at
donatopaolo.mancini@dowjones.com; @donatopmancini
(END) Dow Jones Newswires
January 15, 2019 11:59 ET (16:59 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Apr 2023 to Apr 2024
